methyl 4-methoxybenzimidate hydrochloride | 39739-49-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: methyl 4-methoxybenzimidate hydrochloride
• 英文别名: 4-methoxy-benzimidic acid methyl ester; hydrochloride；4-Methoxy-benzimidsaeure-methylester; Hydrochlorid；4-methoxybenzimidic acid methylester hydrochloride；Methoxy(4-methoxyphenyl)methaniminium chloride；[methoxy-(4-methoxyphenyl)methylidene]azanium;chloride
• CAS: 39739-49-6
• 化学式: C₉H₁₁NO₂*ClH
• 分子量: 201.653
• InChiKey: NIFOAQNRXZPXMI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.09
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  42.3
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  methyl 4-methoxybenzimidate hydrochloride 在 氨 作用下， 以 甲醇 为溶剂， 反应 52.0h， 以31.2 g的产率得到4-甲氧基苄脒盐酸盐
  参考文献：
  名称：

  通过烯炔酮制备 4-乙炔基嘧啶的无过渡金属方法

  摘要：

  已经开发了一种通过芳脒与 2-芳基-1-乙氧基-5-(三甲基甲硅烷基)pent-1-en-4-yn-3-ones 缩合合成 4-ethynylpyrimidines 的实用方法。由于这些后一种酮很容易从双（三甲基甲硅烷基）乙炔和芳基乙酰氯获得，本文报道的区域选择性缩合提供了以高达 85% 的产率轻松获得 TMS 保护和未保护的 4-乙炔基嘧啶的途径。

  DOI：

  10.1002/ejoc.201402045
• 作为产物：
  描述：

  4-甲氧基苯甲腈 以 甲醇 、 ice-water 为溶剂， 生成 methyl 4-methoxybenzimidate hydrochloride
  参考文献：
  名称：

  Pyrimidine derivatives and drugs

  摘要：

  本发明的目的是获得一类新化合物，其在中枢神经系统中具有改善学习和记忆障碍的作用，具有良好的选择性和少量副作用，然后提供一种治疗痴呆症的良好药物。本发明涉及以下一般式所代表的化合物或其药理学上可接受的盐以及包含它们作为活性成分的改善学习或记忆障碍的药物。##STR1##（其中R.sup.1和R.sup.2相同或不同，可以是氢、羟基、烷氧基、三氟甲基或卤素。A代表甲基、三氟甲基或叔丁基。Y代表氧或氨基。）

  公开号：

  US05589477A1

文献信息

• [EN] 6-1H-IMIDAZO-QUINAZOLINE AND QUINOLINES DERIVATIVES, NEW MAO INHIBITORS AND IMIDAZOLINE RECEPTOR LIGANDS<br/>[FR] DÉRIVÉS DE 6-1H-IMIDAZO-QUINAZOLINE ET QUINOLÉINES, NOUVEAUX INHIBITEURS DE MAO ET LIGANDS DES RÉCEPTEURS D'IMIDAZOLINES
  申请人：ROTTAPHARM SPA

  公开号：WO2009152868A1

  公开（公告）日：2009-12-23

  The present invention is directed to 6-(1H-imidazo-1-yl)-2-aryl and 2-heteroaryl quinazoline and quinolines derivatives, compounds of formula (I), their pharmaceutical acceptable salts and solvates and corresponding pharmaceutical compositions, that acts as Monoamine Oxidase (MAO) inhibitors and Imidazoline Receptor ligands: wherein: X is independently selected from -CH group or a nitrogen atom (-N), W is independently selected from an aryl group, an heteroaryl group, or a benzocondensed heteroaryl group such as 1,3-benzodioxole, benzofuran, 2,3-dihydrobenzofuran, benzothiophene, 2,3-dihydrobenzothiophene, indole, 2,3-dihydroindole, benzimidazole, benzoxazole, benzothiazole, 2H-3,4-dihydrobenzopyran, [l,4]-benzodioxine, 2,3-dihydro-[1,4]-benzodioxine (1,4-benzodioxan). R1 is independently selected from hydrogen (-H), C1-C4alkyl, hydroxymethyl (-CH2OH), aminomethyl (-CH2NH2), alkylaminomethyl [CH2NH(R2)], or di-alkylaminomethyl [CH2N(R2)2], trifiuoromethyl (-CF3). Compounds of formula (I) elicited a pharmacological profile suitable for the clinical treatment of depression and related disorders, Parkinson disease, drug abuse, and morphine tolerance and dependence.

  本发明涉及6-(1H-咪唑-1-基)-2-芳基和2-杂芳基喹唑啉和喹啉衍生物，这些衍生物的化学式为(I)，以及它们的药用盐和溶剂化物以及相应的药物组合物，作为单胺氧化酶（MAO）抑制剂和咪唑啉受体配体：其中：X独立地选自-CH基团或氮原子(-N)，W独立地选自芳基团、杂芳基团或如1,3-苯并二氧杂环戊烷、苯并呋喃、2,3-二氢苯并呋喃、苯并噻吩、2,3-二氢苯并噻吩、吲哚、2,3-二氢吲哚、苯并咪唑、苯并噁唑、苯并噻唑、2H-3,4-二氢苯并吡喃、[1,4]-苯并二氧杂环戊烷、2,3-二氢-[1,4]-苯并二氧杂环戊烷(1,4-苯并二氧杂环戊烷)。R1独立地选自氢(-H)、C1-C4烷基、羟甲基(-CH2OH)、氨基甲基(-CH2NH2)、烷基氨甲基[CH2NH(R2)]或二烷基氨甲基[CH2N(R2)2]、三氟甲基(-CF3)。化学式(I)的化合物展现出适合于临床治疗抑郁症和相关障碍、帕金森病、药物滥用以及吗啡耐受性和依赖性的药理特性。
• 6-1H-IMIDAZO-QUINAZOLINE AND QUINOLINES DERIVATIVES, NEW MAO INHIBITORS AND IMIDAZOLINE RECEPTOR LIGANDS
  申请人：Giordani Antonio

  公开号：US20110118289A1

  公开（公告）日：2011-05-19

  The present invention is directed to 6-(1H-imidazo-1-yl)-2-aryl and 2-heteroaryl quinazoline and quinolines derivatives, compounds of formula (I), their pharmaceutical acceptable salts and solvates and corresponding pharmaceutical compositions, that acts as Monoamine Oxidase (MAO) inhibitors and Imidazoline Receptor ligands: wherein: X is independently selected from —CH group or a nitrogen atom (—N), W is independently selected from an aryl group, an heteroaryl group, or a benzocondensed heteroaryl group such as 1,3-benzodioxole, benzofuran, 2,3-dihydrobenzofuran, benzothiophene, 2,3-dihydrobenzothiophene, indole, 2,3-dihydroindole, benzimidazole, benzoxazole, benzothiazole, 2H-3,4-dihydrobenzopyran, [1,4]-benzodioxine, 2,3-dihydro-[1,4]-benzodioxine (1,4-benzodioxan). R 1 is independently selected from hydrogen (—H), C 1 -C 4 alkyl, hydroxymethyl (—CH 2 OH), aminomethyl (—CH 2 NH 2 ), alkylaminomethyl [CH 2 NH(R 2 )], or di-alkylaminomethyl [CH 2 N(R 2 ) 2 ], trifluoromethyl (—CF 3 ). Compounds of formula (I) elicited a pharmacological profile suitable for the clinical treatment of depression and related disorders, Parkinson disease, drug abuse, and morphine tolerance and dependence.

  本发明涉及6-(1H-咪唑-1-基)-2-芳基和2-杂环芳基喹唑啉和喹啉衍生物，公式(I)的化合物，它们的药学可接受的盐和溶剂以及相应的药物组合物，作为单胺氧化酶（MAO）抑制剂和咪唑啉受体配体。其中：X独立地选自—CH基团或氮原子（—N），W独立地选自芳基，杂环芳基或苯并杂环芳基，例如1,3-苯并二氧杂环、苯并呋喃、2,3-二氢苯并呋喃、苯并噻吩、2,3-二氢苯并噻吩、吲哚、2,3-二氢吲哚、苯并咪唑、苯并噁唑、苯并噻唑、2H-3,4-二氢苯并吡喃、[1,4]-苯并二氧茂、2,3-二氢-[1,4]-苯并二氧茂（1,4-苯并二氧杜香）。R1独立地选自氢（—H）、C1-C4烷基、羟甲基（—CH2OH）、氨甲基（—CH2NH2）、烷基氨甲基[CH2NH(R2)]或双烷基氨甲基[CH2N(R2)2]、三氟甲基（—CF3）。公式（I）的化合物表现出适合于临床治疗抑郁症和相关疾病、帕金森病、药物滥用以及吗啡耐受和依赖的药理特性。
• 6-1H-imidazo-quinazoline and quinolines derivatives, new MAO inhibitors and imidazoline receptor ligands
  申请人：Giordani Antonio

  公开号：US08633208B2

  公开（公告）日：2014-01-21

  The present invention is directed to 6-(1H-imidazo-1-yl)-2-aryl and 2-heteroaryl quinazoline and quinolines derivatives, compounds of formula (I), their pharmaceutical acceptable salts and solvates and corresponding pharmaceutical compositions, that acts as Monoamine Oxidase (MAO) inhibitors and Imidazoline Receptor ligands: wherein: X is independently selected from —CH group or a nitrogen atom (—N), W is independently selected from an aryl group, an heteroaryl group, or a benzocondensed heteroaryl group such as 1,3-benzodioxole, benzofuran, 2,3-dihydrobenzofuran, benzothiophene, 2,3-dihydrobenzothiophene, indole, 2,3-dihydroindole, benzimidazole, benzoxazole, benzothiazole, 2H-3,4-dihydrobenzopyran, [1,4]-benzodioxine, 2,3-dihydro-[1,4]-benzodioxine (1,4-benzodioxan). R1 is independently selected from hydrogen (—H), C1-C4 alkyl, hydroxymethyl (—CH2OH), aminomethyl (—CH2NH2), alkylaminomethyl [CH2NH(R2)], or di-alkylaminomethyl [CH2N(R2)2], trifluoromethyl (—CF3). Compounds of formula (I) elicited a pharmacological profile suitable for the clinical treatment of depression and related disorders, Parkinson disease, drug abuse, and morphine tolerance and dependence.

  本发明涉及6-(1H-咪唑-1-基)-2-芳基和2-杂环芳基喹唑啉和喹啉衍生物，化合物的式子为(I)，其药物可接受的盐和溶剂以及相应的药物组合物，可作为单胺氧化酶（MAO）抑制剂和咪唑啉受体配体： 其中：X独立选择自—CH基团或氮原子（—N），W独立选择自芳基、杂环芳基或苯并杂环芳基，如1,3-苯并二氧杂环、苯并呋喃、2,3-二氢苯并呋喃、苯并噻吩、2,3-二氢苯并噻吩、吲哚、2,3-二氢吲哚、苯并咪唑、苯并噁唑、苯并噻唑、2H-3,4-二氢苯并吡喃、[1,4]-苯并二氧茂、2,3-二氢-[1,4]-苯并二氧茂（1,4-苯并二氧杂环）。R1独立选择自氢（—H）、C1-C4烷基、羟甲基（—CH2OH）、氨基甲基（—CH2NH2）、烷基氨基甲基[CH2NH(R2)]或二烷基氨基甲基[CH2N(R2)2]、三氟甲基（—CF3）。 式(I)化合物表现出适合临床治疗抑郁症和相关疾病、帕金森病、药物滥用、吗啡耐受和依赖的药理学特性。
• PYRIMIDINE DERIVATIVE AND MEDICINE
  申请人：NIPPON SHINYAKU COMPANY, LIMITED

  公开号：EP0555478A1

  公开（公告）日：1993-08-18

  The invention aims at obtaining a novel compound which is excellent in central nervous system selectivity and reduced in side effects and has an activity of improving the function of learning and memory, thus providing an excellent medicine for dementia. The invention relates to a compound represented by general formula (I), a pharmacologically acceptable salt thereof, and an agent for remedying the disturbance of learning and memory containing the same as the active ingredient of formula (I), wherein R¹ and R² may be the same or different from each other and each represents hydrogen, hydroxy, alkoxy, trifluoromethyl or halogen; A represents methyl, trifluoromethyl or tertbutyl; and Y represents O or NH.

  本发明旨在获得一种新型化合物，该化合物具有良好的中枢神经系统选择性和较低的副作用，并具有改善学习和记忆功能的活性，从而提供了一种治疗痴呆症的良药。本发明涉及通式(I)代表的化合物、其药理上可接受的盐，以及含有通式(I)活性成分的治疗学习和记忆障碍的药物，其中R¹和R²可以相同或不同，各自代表氢、羟基、烷氧基、三氟甲基或卤素；A代表甲基、三氟甲基或叔丁基；Y代表O或NH。
• Mayer,R. et al., Chemische Berichte, 1966, vol. 99, p. 1393 - 1413
  作者：Mayer,R. et al.

  DOI：——

  日期：——